IMPRiND Project

Innovative Medicines Initiative (IMI): evaluations of IMI1 and IMI2

The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.

The experts conclude that IMI programme ‘remains relevant and justified’ and that ‘positive contributions on the drug development process have been realised’. Positive points recognised in the reports include:

- the IMI role in the creation of collaborative research networks that have enhanced trust between partners from different sectors, and triggered a mind shift as partners came to understand each other’s needs;

- the quality of the research emerging from IMI projects;

- the creation of important resources and tools for drug development, some of which are already being used by researchers in their daily work.

The reports also note that 90% of the people who responded to the online survey agreed that the EU should cooperate with industry in the context of a public-private partnership on health.

Suggestions for improvement concern performance indicators, increasing the involvement of SMEs as well as dissemination and communication of the projects' results.

Read the European Commission's press release on the evaluation

Read the new IMI brochure on results and impacts

Source: IMI

Innovative Medicines Initiative (IMI) 2 Call 13: Indicative Topics Published

IMI 2 has just published a list of indicative topics for the call 13 which is foreseen to be launched before the end of the year.

The following topics are under consideration for inclusion in future IMI calls for proposals:

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches

- Genome-environment interactions in inflammatory skin disease

- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

- Mitochondrial dysfunction in neurodegeneration

- Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative

- A sustainable European induced pluripotent stem cell platform

- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice

- Human tumour microenvironment immunoprofiling

- CONCEPTION - continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now

- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

- Federated and privacy-preserving machine learning in support of drug discovery

- Pilot programme on a clinical compound bank for repurposing. This programme includes the following topics: Cardiovascular diseases and diabetes, Respiratory diseases, Neurodegenerative diseases and Rare/orphan diseases

Source: IMI2

IMPRiND partner Outeiro at Nature Neuroscience: Novel protein interactions explain memory deficits in Parkinson’s disease

IMPRiND partner Tiago Outeiro, Director of the Department of Experimental Neurodegeneration and his team at the University Medical Center Goettingen (UMG), Germany has just published a study in the journal Nature Neuroscience, from Nature publishing group, describing the identification of a novel molecular pathway that can constitute a therapeutic target for cognitive defects in Parkinson’s disease.

It has been shown that abnormal forms of Parkinson’s disease (PD)-associated protein alpha-synuclein interact with the prion protein (PrP), triggering a cascade of events that culminates in neuronal dysfunction, causing cognitive defects that are reminiscent of those in PD.
“This is the follow up of a previous study initiated in my laboratory, where we found that particular forms of the protein alpha-synuclein cause dysfunction of neuronal circuits involved in memory formation. We did not know how this was happening, and in this new study we have detailed the molecular mechanisms involved, which suggests we now have new targets for therapeutic intervention” – explains Tiago Outeiro.

IMPRIND partner Heutink in Science, further supporting the notion that modulating synuclein levels matters in PD​.

A new study with IMPRIND partner Heutink, published in Science, further supports the notion that modulating synuclein levels matters in PD.

IMPRiND full website published today

The IMPRiND full website has been published today. It will be regularly updated with news about the project, results, events etc. Please stay tuned!

Show more posts

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.